Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Attovia Therapeutics, Inc.ATTO · Entity 4984 | Director · President and CEO | August 04, 2026 | October 09, 2026 |
| PORTOLA PHARMACEUTICALS INCPTLA · Entity 147987 | EVP, CBO | August 31, 2018 | September 05, 2018 |
| Zai Lab LtdZLAB · Entity 4271 | Director · President & COO | October 28, 2021 | October 29, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Attovia Therapeutics, Inc.
Report date August 04, 2026 · Filed October 09, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2036-08-03 | Direct | 538,300 |
Reported balance
After 2026-08-04 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-08-04 · Grant · Acquired 538,300 · Balance 538,300 F1: 25% of the options shall vest on August 4, 2027 and the remaining options shall vest in equal monthly installments over the following 36 months, subject to continued service to the Issuer through such dates. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the options shall vest on August 4, 2027 and the remaining options shall vest in equal monthly installments over the following 36 months, subject to continued service to the Issuer through such dates.
PORTOLA PHARMACEUTICALS INC
Report date August 31, 2018 · Filed September 05, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 77,043 |
Ending reported balance
After 2018-09-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-08-31 · Exercise / conversion · Acquired 20,000 · Balance 87,196 F1: Each Performance Stock Unit ("PSU") granted on June 15, 2015 pursuant to the Issuer's 2013 Equity Incentive Plan represented a contingent right to receive one share of Issuer's Common Stock. These PSUs were earned based on achievement of the market performance conditions and were subject to an additional one year period of service. 5,000 of the PSUs vested July 28, 2018 and 20,000 vested on August 31, 2018. Row 2 · 2018-09-04 · Tax withholding · Disposed 10,153 · Balance 77,043 F2: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). |
Filing footnotes · ownership attribution and instrument terms
F1: Each Performance Stock Unit ("PSU") granted on June 15, 2015 pursuant to the Issuer's 2013 Equity Incentive Plan represented a contingent right to receive one share of Issuer's Common Stock. These PSUs were earned based on achievement of the market performance conditions and were subject to an additional one year period of service. 5,000 of the PSUs vested July 28, 2018 and 20,000 vested on August 31, 2018.
F2: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
Zai Lab Ltd
Report date October 28, 2021 · Filed October 29, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | IndirectSee footnote | 77,500 |
Last balance in matching sequence
After 2021-10-28 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 2 · 2021-10-28 · Sale · Disposed 2,065 · Balance 85,435 F1: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person's spouse, dated June 17, 2021, expires February 28, 2022 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2: Reflects a weighted average sale price of $104.49 per share, at prices ranging from $103.77 to $104.76 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F4: Shares held by Reporting Person's spouse. Row 3 · 2021-10-28 · Sale · Disposed 7,935 · Balance 77,500 F1: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person's spouse, dated June 17, 2021, expires February 28, 2022 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3: Reflects a weighted average sale price of $105.13 per share, at prices ranging from $104.87 to $105.40 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F4: Shares held by Reporting Person's spouse. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 187,668 |
Reported balance
Holding disclosure · report date 2021-10-28 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 187,668 |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person's spouse, dated June 17, 2021, expires February 28, 2022 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.
F2: Reflects a weighted average sale price of $104.49 per share, at prices ranging from $103.77 to $104.76 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F3: Reflects a weighted average sale price of $105.13 per share, at prices ranging from $104.87 to $105.40 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F4: Shares held by Reporting Person's spouse.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 19, 2021 Filed Apr 21, 2021 20:01 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 200 | $164.15 | $32,830.00 |
DisclosureSEC source: 0001567619-21-008430 · doc1.xml · nonDerivative · entry 4 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,000 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F4 · price: Reflects a weighted average sale price of $164.15 per share, at prices ranging from $164.14 to $164.15 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 20:01 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 4,000 | $163.38 | $653,520.00 |
DisclosureSEC source: 0001567619-21-008430 · doc1.xml · nonDerivative · entry 3 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,200 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: Reflects a weighted average sale price of $163.38 per share, at prices ranging from $163.05 to $163.78 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 20:01 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 5,800 | $162.55 | $942,790.00 |
DisclosureSEC source: 0001567619-21-008430 · doc1.xml · nonDerivative · entry 2 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,200 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: Reflects a weighted average sale price of $162.55 per share, at prices ranging from $162.02 to $163.00 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 20:01 UTC | Zai Lab Ltd ZLAB · Entity 4271 | Exercise / conversionOrdinary Shares | 10,000 | $18.92 | $189,200.00 |
DisclosureSEC source: 0001567619-21-008430 · doc1.xml · nonDerivative · entry 1 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| March 26, 2021 Filed Mar 30, 2021 18:48 UTC | Zai Lab Ltd ZLAB · Entity 4271 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $18.92 | $0.00 |
DisclosureSEC source: 0000899243-21-013955 · doc4.xml · derivative · entry 3 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 480,000 Underlying: Ordinary Shares · 20,000 shares Expires 2028-09-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person expiring on September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · derivative.exercise_date: The option vests in equal annual installments over five years beginning on 09/24/2019, the first anniversary of the date of grant. Read SEC document |
| March 26, 2021 Filed Mar 30, 2021 18:48 UTC | Zai Lab Ltd ZLAB · Entity 4271 | Exercise / conversionOrdinary Shares | 20,000 | $18.92 | $378,400.00 |
DisclosureSEC source: 0000899243-21-013955 · doc4.xml · nonDerivative · entry 1 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person expiring on September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| September 04, 2018 Filed Sep 5, 2018 19:18 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Tax withholdingCommon Stock | 10,153 | $29.18 | $296,227.99 |
DisclosureSEC source: 0001209191-18-049670 · doc4.xml · nonDerivative · entry 2 Fu Tao · CIK 0001644888 · EVP, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,043 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document |
| August 31, 2018 Filed Sep 5, 2018 19:18 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Exercise / conversionCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-049670 · doc4.xml · nonDerivative · entry 1 Fu Tao · CIK 0001644888 · EVP, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Each Performance Stock Unit ("PSU") granted on June 15, 2015 pursuant to the Issuer's 2013 Equity Incentive Plan represented a contingent right to receive one share of Issuer's Common Stock. These PSUs were earned based on achievement of the market performance conditions and were subject to an additional one year period of service. 5,000 of the PSUs vested July 28, 2018 and 20,000 vested on August 31, 2018. Read SEC document |
| August 23, 2018 Filed Aug 28, 2018 18:06 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Tax withholdingCommon Stock | 2,057 | $26.05 | $53,584.85 |
DisclosureSEC source: 0001209191-18-048729 · doc4.xml · nonDerivative · entry 2 Fu Tao · CIK 0001644888 · EVP, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,196 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document |
| July 28, 2018 Filed Aug 28, 2018 18:06 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Exercise / conversionCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-048729 · doc4.xml · nonDerivative · entry 1 Fu Tao · CIK 0001644888 · EVP, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,253 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Each Performance Stock Unit ("PSU") granted on June 15, 2015 pursuant to the Issuer's 2013 Equity Incentive Plan represented a contingent right to receive one share of Issuer's Common Stock. These PSUs were earned based on achievement of the market performance conditions and were subject to an additional one year period of service. 5,000 of the PSUs vested on July 28, 2018 and 20,000 will vest on August 31, 2018. Read SEC document |
| May 22, 2018 Filed May 24, 2018 20:06 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Tax withholdingCommon Stock | 2,059 | $40.82 | $84,048.38 |
DisclosureSEC source: 0001209191-18-033235 · doc4.xml · nonDerivative · entry 2 Fu Tao · CIK 0001644888 · EVP, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,253 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document |
| May 22, 2018 Filed May 24, 2018 20:06 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantCommon Stock | 5,859 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-033235 · doc4.xml · nonDerivative · entry 1 Fu Tao · CIK 0001644888 · EVP, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,312 F1 · shares: Each Performance Stock Unit ("PSU") granted January 30, 2017 represented a contingent right to receive one share of Issuer's Common Stock. 5,859 PSUs became vested upon the date of the Compensation Committee's certification of regulatory approval of Andexanet alfa in the United States in 2018. 5,859 PSUs will vest on the first anniversary of the Certification Date. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 20:19 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | SaleCommon Stock | 1,135 | $38.47 | $43,663.45 |
DisclosureSEC source: 0001209191-18-019710 · doc4.xml · nonDerivative · entry 1 Fu Tao · CIK 0001644888 · EVP, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,346 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 3, 2017. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 17:52 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Tax withholdingCommon Stock | 5,041 | $32.53 | $163,983.73 |
DisclosureSEC source: 0001209191-18-017417 · doc4.xml · nonDerivative · entry 1 Fu Tao · CIK 0001644888 · EVP, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,498 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 20:05 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $51.31 | $0.00 |
DisclosureSEC source: 0001209191-18-007249 · doc4.xml · derivative · entry 2 Fu Tao · CIK 0001644888 · EVP, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2028-01-30 F2 · derivative.exercise_date: The option shall vest as follows: 1/48th of the shares subject to the option shall vest each month after January 1, 2018, subject to the Reporting Person's Continuous Service as of each such date. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 20:05 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantCommon Stock | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-007249 · doc4.xml · nonDerivative · entry 1 Fu Tao · CIK 0001644888 · EVP, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,750 F1 · shares: Grant of Restricted Stock Units ("RSU") in consideration of services rendered. The RSU vests annually over three years commencing on March 1, 2018, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date. Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 16:46 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Tax withholdingCommon Stock | 1,991 | $54.86 | $109,226.26 |
DisclosureSEC source: 0001209191-17-049635 · doc4.xml · nonDerivative · entry 1 Fu Tao · CIK 0001644888 · EVP, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document |
| July 18, 2017 Filed Jul 20, 2017 19:00 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,812 | $0.00 Strike: $33.49 | $0.00 |
DisclosureSEC source: 0001209191-17-045856 · doc4.xml · derivative · entry 3 Fu Tao · CIK 0001644888 · EVP, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,917 Underlying: Common Stock · 5,812 shares Expires 2026-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017. Read SEC document |
| July 18, 2017 Filed Jul 20, 2017 19:00 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | SaleCommon Stock | 5,812 | $65.00 | $377,780.00 |
DisclosureSEC source: 0001209191-17-045856 · doc4.xml · nonDerivative · entry 2 Fu Tao · CIK 0001644888 · EVP, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · balance_after: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017. Read SEC document |
| July 18, 2017 Filed Jul 20, 2017 19:00 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Exercise / conversionCommon Stock | 5,812 | $33.49 | $194,643.88 |
DisclosureSEC source: 0001209191-17-045856 · doc4.xml · nonDerivative · entry 1 Fu Tao · CIK 0001644888 · EVP, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,812 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017. Read SEC document |
| June 26, 2017 Filed Jun 27, 2017 16:56 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $33.49 | $0.00 |
DisclosureSEC source: 0001209191-17-041966 · doc4.xml · derivative · entry 8 Fu Tao · CIK 0001644888 · EVP, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,999 Underlying: Common Stock · 3,000 shares Expires 2026-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017. Read SEC document |
| June 26, 2017 Filed Jun 27, 2017 16:56 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | SaleCommon Stock | 3,000 | $60.00 | $180,000.00 |
DisclosureSEC source: 0001209191-17-041966 · doc4.xml · nonDerivative · entry 5 Fu Tao · CIK 0001644888 · EVP, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · balance_after: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017. Read SEC document |
| June 26, 2017 Filed Jun 27, 2017 16:56 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Exercise / conversionCommon Stock | 3,000 | $33.49 | $100,470.00 |
DisclosureSEC source: 0001209191-17-041966 · doc4.xml · nonDerivative · entry 4 Fu Tao · CIK 0001644888 · EVP, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017. Read SEC document |
| June 23, 2017 Filed Jun 27, 2017 16:56 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,396 | $0.00 Strike: $33.49 | $0.00 |
DisclosureSEC source: 0001209191-17-041966 · doc4.xml · derivative · entry 7 Fu Tao · CIK 0001644888 · EVP, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,999 Underlying: Common Stock · 1,396 shares Expires 2026-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017. Read SEC document |
| June 23, 2017 Filed Jun 27, 2017 16:56 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,604 | $0.00 Strike: $25.54 | $0.00 |
DisclosureSEC source: 0001209191-17-041966 · doc4.xml · derivative · entry 6 Fu Tao · CIK 0001644888 · EVP, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,906 Underlying: Common Stock · 2,604 shares Expires 2027-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017. Read SEC document |
| June 23, 2017 Filed Jun 27, 2017 16:56 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | SaleCommon Stock | 4,000 | $55.00 | $220,000.00 |
DisclosureSEC source: 0001209191-17-041966 · doc4.xml · nonDerivative · entry 3 Fu Tao · CIK 0001644888 · EVP, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · balance_after: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017. Read SEC document |
| June 23, 2017 Filed Jun 27, 2017 16:56 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Exercise / conversionCommon Stock | 1,396 | $33.49 | $46,752.04 |
DisclosureSEC source: 0001209191-17-041966 · doc4.xml · nonDerivative · entry 2 Fu Tao · CIK 0001644888 · EVP, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,396 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017. Read SEC document |
| June 23, 2017 Filed Jun 27, 2017 16:56 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Exercise / conversionCommon Stock | 2,604 | $25.54 | $66,506.16 |
DisclosureSEC source: 0001209191-17-041966 · doc4.xml · nonDerivative · entry 1 Fu Tao · CIK 0001644888 · EVP, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017. Read SEC document |
| April 10, 2017 Filed Apr 11, 2017 16:31 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | SaleCommon Stock | 1,097 | $36.97 | $40,556.09 |
DisclosureSEC source: 0001209191-17-026572 · doc4.xml · nonDerivative · entry 1 Fu Tao · CIK 0001644888 · EVP, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.32 to $37.17, inclusive. Read SEC document |
| March 02, 2017 Filed Mar 3, 2017 17:34 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Tax withholdingCommon Stock | 3,494 | $38.61 | $134,903.34 |
DisclosureSEC source: 0001209191-17-017814 · doc4.xml · nonDerivative · entry 1 Fu Tao · CIK 0001644888 · EVP, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,319 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document |
| January 30, 2017 Filed Feb 1, 2017 19:55 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantPerformance Stock Unit · Derivative | 15,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-006885 · doc4.xml · derivative · entry 3 Fu Tao · CIK 0001644888 · EVP, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,625 Underlying: Common Stock · 15,625 shares Expires 2027-01-30 F3 · derivative.exercise_price: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of Issuer's Common Stock. The PSUs vest as follows: (i) 50% of the PSUs will become vested upon the date of the Compensation Committee's certification of regulatory approval of Andexanet alfa in either the United States or European Union (the "Certification Date") in 2017, with the remaining 50% vesting on the first anniversary of the Certification Date, or (ii) 37.5% of the PSUs will become vested upon the Certification Date in 2018, with the remaining 37.5% vesting on the first anniversary of the Certification Date. If the Certification Date does not occur prior to the end of 2018, the PSUs shall not vest. F3 · derivative.exercise_date: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of Issuer's Common Stock. The PSUs vest as follows: (i) 50% of the PSUs will become vested upon the date of the Compensation Committee's certification of regulatory approval of Andexanet alfa in either the United States or European Union (the "Certification Date") in 2017, with the remaining 50% vesting on the first anniversary of the Certification Date, or (ii) 37.5% of the PSUs will become vested upon the Certification Date in 2018, with the remaining 37.5% vesting on the first anniversary of the Certification Date. If the Certification Date does not occur prior to the end of 2018, the PSUs shall not vest. Read SEC document |
| January 30, 2017 Filed Feb 1, 2017 19:55 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantStock Option (Right to Buy) · Derivative | 62,500 | $0.00 Strike: $25.54 | $0.00 |
DisclosureSEC source: 0001209191-17-006885 · doc4.xml · derivative · entry 2 Fu Tao · CIK 0001644888 · EVP, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2027-01-30 F2 · derivative.exercise_date: The option shares shall vest as follows: 1/48th of the shares subject to the option shall vest each month after January 1, 2017, subject to the Reporting Person's Continuous Service as of each such date. Read SEC document |
| January 30, 2017 Filed Feb 1, 2017 19:55 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantCommon Stock | 15,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-006885 · doc4.xml · nonDerivative · entry 1 Fu Tao · CIK 0001644888 · EVP, CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,625 F1 · shares: Grant of Restricted Stock Units ("RSU") in consideration of services rendered. The RSU vests annually over three years commencing on March 1, 2017, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.